Holen Sie sich die Stockscreener-App
1.045
2.45%
0.025
Schlusskurs vom Vortag:
$1.02
Offen:
$1.02
24-Stunden-Volumen:
2.42M
Relative Volume:
0.68
Marktkapitalisierung:
$280.33M
Einnahmen:
$236.20M
Nettoeinkommen (Verlust:
$-5.35M
KGV:
-58.38
EPS:
-0.0179
Netto-Cashflow:
$67.70M
1W Leistung:
+16.75%
1M Leistung:
-26.92%
6M Leistung:
-34.28%
1J Leistung:
-63.46%
1-Tages-Spanne:
$1.019
$1.08
1-Wochen-Bereich:
$0.8953
$1.08
52-Wochen-Spanne:
$0.875
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.045 | 273.62M | 236.20M | -5.35M | 67.70M | -0.0179 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.26 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.74 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.81 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.01 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Promising Penny Stocks To Consider In May 2026 - Yahoo Finance
AKBA Technical Analysis & Stock Price Forecast - Intellectia AI
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Akebia plunges 20% on muted Q1 print - MSN
Number of shareholders of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Earnings call transcript: Akebia Therapeutics Q1 2026 reports EPS miss, stock falls - Investing.com Canada
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia - Stock Titan
HC Wainwright Issues Negative Estimate for AKBA Earnings - MarketBeat
TradingKey - TradingKey
Akebia outlines phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients - MSN
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results - simplywall.st
Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results - Yahoo Finance
Akebia Q1 2026 earnings preview - MSN
HC Wainwright Expects Lower Earnings for Akebia Therapeutics - MarketBeat
Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan - Sahm
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics (AKBA) Receives a Buy from H.C. Wainwright - The Globe and Mail
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Akebia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Akebia Therapeutics(AKBA) Stock Options Chain | Quotes & News - Moomoo
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Akebia (AKBA) Q1 2026 Earnings Transcript - AOL.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA): Is Breakeven Near? - 富途牛牛
Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript - GuruFocus
AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Zacks Research - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: A Biotech with Significant Upside Potential - DirectorsTalk Interviews
Akebia Therapeutics (AKBA) Losses Narrow To US$9.1 Million Challenging Bearish Profitability Narratives - Sahm
Akebia Therapeutics (NASDAQ:AKBA) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Akebia Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Akebia Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Akebia Therapeutics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Akebia’s Q1 2026 results miss forecasts, stock drops - Investing.com Canada
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Akebia Therapeutics (NASDAQ: AKBA) swings to Q1 2026 loss amid new Auryxia generic - Stock Titan
AKBA: Vafseo growth and pipeline advances offset Auryxia declines, with cash to fund operations for two years - TradingView
Akebia Therapeutics: Q1 Earnings Snapshot - KVUE
Akebia (NASDAQ: AKBA) Q1 2026 loss amid Auryxia decline, Vafseo growth - Stock Titan
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights - GlobeNewswire
MSN Money - MSN
Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Akebia Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Akebia gives 7 new hires stock options tied to 208,800 shares - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akebia Therapeutics Inc-Aktie (AKBA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malabre Richard C | SVP, Chief Accounting Officer |
Feb 02 '26 |
Sale |
1.39 |
49,524 |
68,838 |
299,390 |
| Grund Nicholas | Chief Commercial Officer |
Feb 02 '26 |
Sale |
1.39 |
84,829 |
117,912 |
561,750 |
| Burke Steven Keith | SVP, Chief Medical Officer |
Feb 02 '26 |
Sale |
1.39 |
67,658 |
94,045 |
948,432 |
| Rucci Carolyn M. | SVP, Chief Legal Officer |
Feb 02 '26 |
Sale |
1.39 |
69,772 |
96,983 |
588,378 |
| Ostrowski Erik | SVP, CFO, CBO & Treasurer |
Feb 02 '26 |
Sale |
1.39 |
34,951 |
48,582 |
672,635 |
| Butler John P. | CEO and President |
Feb 02 '26 |
Sale |
1.39 |
341,305 |
474,414 |
3,206,233 |
1.38%
1.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):